Macquarie Group
PSTV icon

Macquarie Group’s Plus Therapeutics PSTV Stock Holding History

Macquarie Group’s Portfolio PSTV Stock Details PSTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Hold
0
– -$2K – 1952
2018
Q4 		– Hold
0
– – – 2198
2018
Q3 		– Sell
-2
Closed -$29K – 2240
2018
Q2 		$29K Buy
+2
New +$95.2K ﹤0.01% 2022
2018
Q1 		– Hold
0
– -$10K – 2326
2017
Q4 		– Hold
0
– – – 2261

Other funds holding PSTV

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MOS
MGO One Seven Beachwood, Ohio $4.98B AUM 22.72% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Macquarie Group's PSTV Position: Q1 2019 in Review

Macquarie Group held its Plus Therapeutics (PSTV) position steady in Q1 2019 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1952.

Macquarie Group first reported a position in PSTV in Q2 2018 and has held it in 1 quarter since. The position peaked at $29K in Q2 2018. 7 funds tracked by Wall St. Rank hold PSTV as of Q1 2019.

  • Macquarie Group held 0 shares of Plus Therapeutics worth $0 as of Q1 2019.
  • Macquarie Group left its Plus Therapeutics share count unchanged in Q1 2019.
  • Plus Therapeutics made up ﹤0.01% of Macquarie Group's portfolio in Q1 2019, its #1952 holding.
  • Macquarie Group first reported a position in Plus Therapeutics in Q2 2018 and has held it in 1 quarter since.
  • Macquarie Group's Plus Therapeutics position peaked at $29K in Q2 2018.
  • 7 funds tracked by Wall St. Rank held Plus Therapeutics as of Q1 2019.

Based on Macquarie Group's 13F filing for Q1 2019, filed 15 May 2019.